Although this needs to be experimentally demonstrated in the context of a B cell lymphoma, it suggests that targeting the intact paralog in those lymphoma cases that harbor a c-MYC activation would eliminate cancer cells and represent a rather specific therapeutic strategy. The gene discussed is MYC; the disease is lymphoma.